NZ590784A - Pyrazolopyridine kinase inhibitors - Google Patents

Pyrazolopyridine kinase inhibitors

Info

Publication number
NZ590784A
NZ590784A NZ59078409A NZ59078409A NZ590784A NZ 590784 A NZ590784 A NZ 590784A NZ 59078409 A NZ59078409 A NZ 59078409A NZ 59078409 A NZ59078409 A NZ 59078409A NZ 590784 A NZ590784 A NZ 590784A
Authority
NZ
New Zealand
Prior art keywords
pyridin
optionally
independently
ring
independently substituted
Prior art date
Application number
NZ59078409A
Other languages
English (en)
Inventor
Juan-Miguel Jimenez
Luca Settimo
Damien Fraysse
Guy Brenchley
Dean Boyall
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NZ590784A publication Critical patent/NZ590784A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K39/00—Feeding or drinking appliances for poultry or other birds
    • A01K39/01—Feeding devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Environmental Sciences (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Birds (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
NZ59078409A 2008-07-23 2009-07-22 Pyrazolopyridine kinase inhibitors NZ590784A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8292908P 2008-07-23 2008-07-23
US14010108P 2008-12-23 2008-12-23
US16317609P 2009-03-25 2009-03-25
PCT/US2009/051413 WO2010011756A1 (en) 2008-07-23 2009-07-22 Pyrazolopyridine kinase inhibitors

Publications (1)

Publication Number Publication Date
NZ590784A true NZ590784A (en) 2012-12-21

Family

ID=41327642

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ59078409A NZ590784A (en) 2008-07-23 2009-07-22 Pyrazolopyridine kinase inhibitors

Country Status (12)

Country Link
US (2) US9137973B2 (enExample)
EP (1) EP2318407B1 (enExample)
JP (2) JP2011529062A (enExample)
KR (1) KR20110039563A (enExample)
CN (1) CN102131807B (enExample)
AU (1) AU2009274011B2 (enExample)
CA (1) CA2731451A1 (enExample)
ES (1) ES2402087T3 (enExample)
IL (1) IL210821A0 (enExample)
MX (1) MX2011000839A (enExample)
NZ (1) NZ590784A (enExample)
WO (1) WO2010011756A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
MX2011001319A (es) 2008-08-06 2011-04-05 Vertex Pharma Inhibidores de aminopiridina cinasa.
GEP20207129B (en) 2009-06-17 2020-07-10 Vertex Pharma Inhibitors of influenza viruses replication
EP2528917B1 (en) * 2010-01-27 2016-10-19 Vertex Pharmaceuticals Incorporated Pyrazolopyridines useful for the treatment of autoimmune, inflammatory or (hyper)proliferative diseases
MX2012008642A (es) * 2010-01-27 2012-11-23 Vertex Pharma Inhibidores de cinasas de pirazolopiridinas.
JP2013545817A (ja) 2010-12-16 2013-12-26 バーテックス ファーマシューティカルズ インコーポレイテッド インフルエンザウイルス複製阻害物質
AU2011343647A1 (en) 2010-12-16 2013-05-02 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
RU2013132681A (ru) 2010-12-16 2015-01-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы репликации вирусов гриппа
UA118010C2 (uk) * 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
SG11201406584TA (en) 2012-04-24 2014-11-27 Vertex Pharma Dna-pk inhibitors
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
WO2013184985A1 (en) 2012-06-08 2013-12-12 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
EP2909206A1 (en) * 2012-10-16 2015-08-26 F. Hoffmann-La Roche AG Serine/threonine kinase inhibitors
RS62649B1 (sr) 2013-03-12 2021-12-31 Vertex Pharma Inhibitori dnk-pk
KR102411227B1 (ko) 2013-10-17 2022-06-21 버텍스 파마슈티칼스 인코포레이티드 Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정
PT3068776T (pt) 2013-11-13 2019-08-26 Vertex Pharma Inibidores da replicação de vírus da gripe
HUE038820T2 (hu) 2013-11-13 2018-11-28 Vertex Pharma Eljárás influenzavírusok replikációjának inhibitorai elõállítására
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
CN105254628B (zh) * 2015-11-13 2017-06-23 南京华威医药科技开发有限公司 吡唑并吡啶类抗肿瘤化合物及其制备方法和应用
CN105503863A (zh) * 2015-12-11 2016-04-20 南京华威医药科技开发有限公司 新型抗肿瘤化合物
CN105503865A (zh) * 2015-12-24 2016-04-20 南京华威医药科技开发有限公司 新型吡唑并吡啶类抗肿瘤化合物
US9825597B2 (en) 2015-12-30 2017-11-21 Skyworks Solutions, Inc. Impedance transformation circuit for amplifier
KR102629723B1 (ko) 2016-04-19 2024-01-30 스카이워크스 솔루션즈, 인코포레이티드 무선 주파수 모듈의 선택적 차폐
MX394860B (es) 2016-09-27 2025-03-24 Vertex Pharma Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
TWI907080B (zh) 2016-12-29 2025-12-01 美商天工方案公司 封裝模組、無線通信裝置及射頻信號傳輸方法
US10515924B2 (en) 2017-03-10 2019-12-24 Skyworks Solutions, Inc. Radio frequency modules
CN113423707A (zh) * 2018-11-16 2021-09-21 加利福尼亚技术学院 Erk抑制剂及其用途
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ｃｋ１２抑制劑
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3853898A (en) 1971-07-20 1974-12-10 Sandoz Ag 3-(2-substituted amino) pyridyl-phenyl ketone imines
US4988705A (en) 1985-06-13 1991-01-29 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
FR2601015B1 (fr) 1986-07-04 1988-08-05 Rhone Poulenc Sante Nouveaux derives du 1h,3h-pyrrolo (1,2-c) thiazole, leur preparation et les compositions pharmaceutiques qui les contiennent
DE3827253A1 (de) 1987-08-20 1989-03-02 Sandoz Ag Ester und amide von cyclischen carbonsaeuren und cyclischen alkoholen und aminen sowie verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
CA1339423C (en) 1988-09-14 1997-09-02 Yuji Ono Pyridine compounds and pharmaceutical use thereof
US5100768A (en) 1989-05-09 1992-03-31 Kabushiki Kaisha Toshiba Photosensitive composition
JPH03206450A (ja) 1990-01-09 1991-09-09 Fuji Photo Film Co Ltd 新規な色素形成カプラー及びそれを用いたハロゲン化銀カラー写真感光材料及びその処理方法
US5308854A (en) 1990-06-18 1994-05-03 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
JPH05331163A (ja) 1991-03-26 1993-12-14 Kumiai Chem Ind Co Ltd ピリジン誘導体及び除草剤
UA44220C2 (uk) 1991-11-07 2002-02-15 Агрево Юк Лімітед Сульфонаміди,що мають гербіцидну активність,спосіб їх одержання, гербіцидна композиція та спосіб боротьби з бур'янами
US5476750A (en) 1992-12-29 1995-12-19 Hoechst Celanese Corporation Metal ion reduction in the raw materials and using a Lewis base to control molecular weight of novolak resin to be used in positive photoresists
DE69404306T2 (de) 1993-05-28 1997-10-30 Pfizer Verfahren zur herstellung und optischen auflösung von 2-phenyl-3-aminopiperidine
CA2133355A1 (en) 1993-10-04 1995-04-05 Itaru Nitta Method for producing polypeptide
WO1995032963A1 (en) 1994-06-01 1995-12-07 Yoshitomi Pharmaceutical Industries, Ltd. Thienylazole compound and thienotriazolodiazepine compound
WO1996006843A1 (en) 1994-08-29 1996-03-07 Yamanouchi Pharmaceutical Co., Ltd. Novel naphthyridine derivative and medicinal composition thereof
US5646330A (en) 1995-02-17 1997-07-08 Ciba-Geigy Corporation Production of enantiomerically enriched ortho-substituted α,α-diaromatic methanols
US6194581B1 (en) 1995-04-07 2001-02-27 Merck & Co., Inc. Substituted pyridines useful as modulators of acetylcholine receptors
NZ322197A (en) 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
IL132391A0 (en) 1997-04-18 2001-03-19 Kissei Pharmaceutical Preventives or remedies for diseases effecting excessive proliferation or retinal pigment eptihelial cells
WO1998057957A1 (en) 1997-06-18 1998-12-23 Nissan Chemical Industries, Ltd. Pyridine compounds and herbicides
US6452008B2 (en) 1998-02-25 2002-09-17 Sumitomo Pharmaceuticals Company, Limited Pyridone derivatives and process for preparing the same
US6225329B1 (en) 1998-03-12 2001-05-01 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
GB9908410D0 (en) 1999-04-13 1999-06-09 Pfizer Ltd Pyridines
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
AU2001257490A1 (en) 2000-05-02 2001-11-12 Newbiotics, Inc. Improved beta-lactam antibiotics
AR029289A1 (es) 2000-07-05 2003-06-18 Ishihara Sangyo Kaisha Derivado de benzoilpiridina o su sal, fungicida que lo contiene como un ingrediente activo, su proceso de produccion e intermediario para producirlo
DE10035908A1 (de) 2000-07-21 2002-03-07 Asta Medica Ag Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel
NZ525591A (en) 2000-10-05 2004-04-30 Fujisawa Pharmaceutical Co Benzamide compounds as Apo B secretion inhibitors
ES2200617B1 (es) 2001-01-19 2005-05-01 Almirall Prodesfarma, S.A. Derivados de urea como antagonistas de integrinas alfa 4.
GB2373245A (en) 2001-03-12 2002-09-18 Bayer Ag Pyridinyl pyrazoles and their use for the treatment of COPD
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
IL161662A0 (en) 2001-11-01 2004-09-27 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors (gsk3 inhibitors)
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AU2003248549B2 (en) 2002-05-24 2010-04-08 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
US7186716B2 (en) * 2002-08-12 2007-03-06 Sugen, Inc. 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
CN102503903A (zh) 2003-02-07 2012-06-20 詹森药业有限公司 抑制hiv的1,2,4-三嗪
EP1601664B1 (en) 2003-02-28 2008-04-30 Schering Corporation Biaryltetrahydroisoquinoline piperidines as selective mch receptor antagonists for the treatment of obesity and related disorders
AU2004233827B2 (en) * 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US20050203067A1 (en) 2003-05-12 2005-09-15 Hresko Michelle C. Pesticidal compositions and methods
WO2005000813A1 (en) 2003-05-30 2005-01-06 Imclone Systems Incorporated Heteroarylamino-phenylketone derivatives and their use as kinase inhibitors
CA2533626A1 (en) 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
ES2361835T3 (es) 2003-09-25 2011-06-22 Janssen Pharmaceutica Nv Derivados de purina inhibidores de la replicación del hiv.
EP1689722A2 (en) 2003-10-10 2006-08-16 Bayer Pharmaceuticals Corporation 4-aminopyrimidine derivatives for treatment of hyperproliferative disorders
CN101061101B (zh) 2003-12-22 2011-09-07 巴斯利尔药物股份公司 芳酰基呋喃和芳酰基噻吩
ES2364340T3 (es) * 2004-03-30 2011-08-31 Vertex Pharmaceuticals Incorporated Azaindoles útiles como inhibidores de jak y otras proteína quinasas.
US7514448B2 (en) * 2004-04-02 2009-04-07 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of rock and other protein kinases
EP1751119A1 (en) 2004-05-19 2007-02-14 AstraZeneca AB Novel fused heterocycles and uses thereof
US7626021B2 (en) * 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
NZ553267A (en) 2004-07-27 2010-09-30 Sgx Pharmaceuticals Inc Pyrrolo-pyridine kinase modulators
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7709645B2 (en) 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
JPWO2006016548A1 (ja) 2004-08-09 2008-05-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環化合物を含有する新規な抗マラリア剤
AU2005309566A1 (en) * 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or Rho kinase
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
ES2345997T3 (es) 2005-01-14 2010-10-07 Janssen Pharmaceutica Nv Pirazolopiramidinas como inhibidores de las quinasas del ciclo celular.
PT1863818E (pt) 2005-03-23 2010-04-09 Hoffmann La Roche Derivados de acetilenil-pirazolo-pirimidina como antagonistas de mglur2
JP5180816B2 (ja) 2005-04-04 2013-04-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 神経変性疾患および認知症のためのジヒドロピリジン化合物
RU2007141401A (ru) 2005-04-08 2009-05-20 ЭЙСАЙ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД. (JP) Терапевтический агент для лечения дискинезии
AU2006247322A1 (en) * 2005-05-16 2006-11-23 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
NZ592968A (en) * 2006-01-17 2012-08-31 Vertex Pharma Azaindoles substituted with either triazine or pyrimidine useful as inhibitors of janus kinases consisting of JAK1, JAK2, JAK3, and TYK2
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
EP2121613A2 (en) 2007-01-31 2009-11-25 Vertex Pharmaceuticals, Inc. 2-aminopyridine derivatives useful as kinase inhibitors

Also Published As

Publication number Publication date
US9137973B2 (en) 2015-09-22
AU2009274011A1 (en) 2010-01-28
MX2011000839A (es) 2011-04-05
ES2402087T3 (es) 2013-04-26
EP2318407A1 (en) 2011-05-11
CN102131807A (zh) 2011-07-20
US20140148434A1 (en) 2014-05-29
CN102131807B (zh) 2013-11-20
JP2011529062A (ja) 2011-12-01
WO2010011756A1 (en) 2010-01-28
KR20110039563A (ko) 2011-04-19
HK1156026A1 (en) 2012-06-01
EP2318407B1 (en) 2013-01-02
US20120184524A1 (en) 2012-07-19
AU2009274011B2 (en) 2014-12-18
JP2014237702A (ja) 2014-12-18
US9029546B2 (en) 2015-05-12
IL210821A0 (en) 2011-04-28
CA2731451A1 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
NO991423L (no) Kinolinderivater som inhiberer effekten av vekstfaktorer som VEGF
HRP20201094T1 (hr) IMIDAZO[1,2-a]PIRIDINI, NAMIJENJENI LIJEČENJU ILI SPRJEČAVANJU HIPERURIKEMIJE ILI GIHTA
HRP20180483T1 (hr) Spoj kinolona
SI2989100T1 (en) NAFTIRIDINE DERIVATIVES USED AS ANTAGONISTS INTEGRITY OF ALFA-V-BETA-6
NZ600229A (en) Triazolopyridines
NZ605432A (en) 2-(arylamino)-3h-imidazo[4,5-b]pyridine-6-carboxamide derivatives and their use as mpges-1 inhibitors
NZ597533A (en) Apoptosis signal-regulating kinase inhibitors
TW200716648A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
RU2014105169A (ru) 2-пиридилзамещенные имидазолы в качестве ингибиторов alk5 и/или alk4
ME02203B (me) Hinolin i hinoksalin derivati kao inhibitori kinaza
GEP20156417B (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
CL2008003810A1 (es) Compuestos derivados de 5-anilino imidazol[1,5-a]piridina o pirazina, inhibidores de la actividad mek quinasa; composiciones farmaceuticas que los contienen; y su uso para tratar trastornos hiperproliferativos y una enfermedad inflamatoria.
SI2925757T1 (en) Compounds and compositions for the treatment of parasitic diseases
ME02409B (me) Novi heterociklični derivati i njihova upotreba u tretmanu neuroloških poremećaja
JP2013515692A5 (enExample)
WO2008115098A3 (fr) 2,3,4,5-tétrahydro-1h-pyrido[4,3-b]indoles substitués ainsi que procédés de leur fabrication et leur utilisation
EA201300620A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИМИДАЗО[4,5-b]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ JAK
CA2596013A1 (en) Benzoimidazole derivatives and pharmaceutical composition comprising the same
HRP20160852T1 (hr) Biciklični heterociklični spojevi kao inhibitori protein tirozin kinaze
HRP20130846T1 (hr) Derivati indolizina i njihova uporaba u medicinske svrhe
HRP20171040T1 (hr) Supstituirani biciklički dihidropirimidinoni i njihova uporaba za inhibiranje djelovanja elastaze neutrofila
PE20081159A1 (es) Inhibidores de las quinasas y metodos para su utilizacion
RU2013138834A (ru) N-[3-(5-амино-3,3а,7,7а-тетрагидро-1н-2,4-диокса-6-аза-инден-7-ил)-фенил]-амиды в качестве ингибиторов васе1 и(или) васе2
JP2016540803A5 (enExample)
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 22 JUL 2016 BY COMPUTER PACKAGES INC

Effective date: 20130726

ERR Error or correction

Free format text: THE OWNER HAS BEEN CORRECTED TO 3155030, VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON, MASSACHUSETTS 02210, US

Effective date: 20150127

LAPS Patent lapsed